Results 21 to 30 of about 4,412 (151)

Ischemic stroke following COVID-19 vaccination [PDF]

Journal of Research in Clinical Medicine, 2023
Following the coronavirus disease 2019 (COVID-19) vaccination, complications are expected. In this regard, coagulopathy after COVID-19 vaccination has been reported.
Nooshin Masoudian, Maryam Kakovan, Samaneh Ghorbani Shirkouhi, Fatemeh Ehsani, Sasan Andalib   +4 more
doaj   +1 more source

Comparison of the Safety and Immunogenicity of FAKHRAVAC and BBIBP-CorV Vaccines when Administrated as Booster Dose: A Parallel Two Arms, Randomized, Double Blind Clinical Trial

Vaccines, 2022
Purpose: This study was completed to assess the immunogenicity and safety of the FAKHRAVAC and BBIBP-CorV vaccines as a booster dose in the population with a history of receiving two doses of BBIBP-CorV vaccine.
Mohammadreza Ahi, Ramin Hamidi Farahani, Pouria Basiri, Ahmad Karimi Rahjerdi, Ali Sheidaei, Kimiya Gohari, Zahra Rahimi, Fatemeh Gholami, Milad Moradi, Farzad Ghafoori Naeeni, Kosar Naderi Saffar, Soheil Ghasemi, Babak Barati, Sohrab Moradi, Arina Monazah, Fatemeh Pouranvari, Mohsen Forooghizadeh   +16 more
doaj   +1 more source

RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine

BMC Infectious Diseases, 2022
Background Limited information is available on the effectiveness of the BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine, especially in the elderly, despite the fact that it is approved in more than 50 countries.
Tamás Ferenci, Balázs Sarkadi
doaj   +1 more source

Comparison of immune activation of the COVID vaccines : ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based [PDF]

, 2022
To gain insight into the different protective mechanisms of approved vaccines, this study focuses on the comparison of humoral and cellular immune responses of five widely used vaccines including ChAdOx1 (AZD1222, AstraZeneca), BNT162b2 (Pfizer), mRNA ...
Bukva Mátyás, Fodor Eszter, Földes Fanni Vivien, Hamar E, Hetényi Roland, Hinsenkamp Adél Gyöngyvér, Hornyák István, Jakab Ferenc, Kemenesi Gábor, Kuten-Pella O, Lacza Zsombor, Madár Á, Olmos Calvo I, Zana Brigitta   +13 more
core   +4 more sources

Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco

BMC Public Health, 2022
Background The Kingdom of Morocco approved BBIBP-CorV (Sinopharm) COVID-19 vaccine for emergency use on 22 January 2021 in a two-dose, three-to-four-week interval schedule.
Yaowen Zhang, Jihane Belayachi, Yunkai Yang, Qiang Fu, Lance Rodewald, Hongling Li, Bing Yan, Ying Wang, Yanna Shen, Qian Yang, Weiyun Mu, Rong Tang, Chen Su, Tianfang Xu, Majdouline Obtel, Abdelkader Mhayi, Rachid Razine, Redouane Abouqal, Yuntao Zhang, Xiaoming Yang   +19 more
doaj   +1 more source

IgG Antibody Responses and Immune Persistence of Two Doses of BBIBP-CorV Vaccine or CoronaVac Vaccine in People Living with HIV (PLWH) in Shenzhen, China

Vaccines, 2022
The purpose of this study was to preliminarily evaluate the immunogenicity and immune persistence of inactivated SARS-CoV-2 vaccines in PLWH in the real world.
Guang Zeng, Liumei Xu, Shuidong Feng, Jie Tang, Xiaohui Wang, Guilian Li, Yongxia Gan, Chenli Zheng, Jin Zhao, Zhengrong Yang   +9 more
doaj   +1 more source

Post-vaccination seropositivity against SARS-CoV-2 in peruvian health workers vaccinated with BBIBP-CorV (Sinopharm) [PDF]

, 2022
Objective: To estimate the prevalence of post-vaccination seropositivity against SARS-CoV-2 and identify its predictors in Peruvian Social Health Insurance (EsSalud) personnel in 2021.
Alvizuri Pastor, Sergio, Apolaya Segura, Moises, Carrillo Ramos, Elizabeth, Contreras Macazana, Roxana, Cvetkovic Vega, Aleksandar, Fernandez Bolivar, Lizette, Figueroa Montes, Luis E., Grande Castro, Nikolai, Lecca Rengifo, Diana, Maguina, Jorge L., Neyra Vera, Ibeth, Oyanguren Miranda, Martin, Sagástegui, Arturo, Soto Becerra, Percy, Urrunaga Pastor, Diego   +14 more
core   +1 more source

Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination

iScience, 2022
Summary: The emergence of the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant has raised questions regarding resistance to neutralizing antibodies elicited by natural infection or immunization.
Li-Jun Duan, Wen-Guo Jiang, Zhuang-Ye Wang, Lin Yao, Ka-Li Zhu, Qing-Chuan Meng, Bao-Shan Wang, Li-Bo Li, Guo-Lin Wang, Mai-Juan Ma   +9 more
doaj   +1 more source

Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2 [PDF]

, 2022
SARS-CoV-2-specific humoral response was analyzed over time in a group of healthcare workers with or without exposure to SARS-CoV-2, who underwent vaccination with BBIBP-CorV (Sinopharm) vaccine in Argentina.
Aloisi, Natalia, Badano, Maria Noel, Baré, Patricia, Castillo, Luis, Chuit, Roberto, Colado, Ana, Elizalde de Bracco, María Marta, Fink, Susana, Keitelman, Irene Angélica, Ortiz Wilczyñski, Juan Manuel, Pereson Moschen, Matias Javier, Pozner, Roberto Gabriel, Ramos, Maria Victoria, Sabbione, Florencia, Wigdorovitz, Georgina   +14 more
core   +1 more source

PastoCovac and PastoCovac Plus as protein subunit COVID-19 vaccines led to great humoral immune responses in BBIP-CorV immunized individuals

Scientific Reports, 2023
The optimal booster vaccine schedule against COVID-19 is still being explored. The present study aimed at assessment of the immunogenicity and antibody persistency of inactivated-virus based vaccine, BBIP-CorV and protein-subunit based vaccines ...
Amitis Ramezani, Rahim Sorouri, Saiedeh Haji Maghsoudi, Sarah Dahmardeh, Delaram Doroud, Mona Sadat Larijani, Sana Eybpoosh, Ehsan Mostafavi, Alireza Olyaeemanesh, Mostafa Salehi-Vaziri, Anahita Bavand, Ghazaleh Zarghani, Ladan Moradi, Fatemeh Ashrafian, Fahimeh Bagheri Amiri, Parisa Mashayekhi, Zahra Tahmasebi, Alireza Biglari   +17 more
doaj   +1 more source